HK inno.N Corporation
Clinical trials sponsored by HK inno.N Corporation, explained in plain language.
A pharmaceutical company developing and commercializing drugs and healthcare products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New injection aims to shed pounds in major obesity trial Results expected Dec 2026 (estimated)
- New GERD drug tegoprazan tested in large real-world study Results expected Jun 2027 (estimated)
- New diabetes shot aims to lower blood sugar in patients not helped by diet alone Results expected Aug 2027 (estimated)
-
New ointment aims to calm eczema: early trial tests safety
Disease control CompletedResearchers are testing an experimental ointment called IN-A002 for mild to moderate atopic dermatitis, a common skin condition that causes itchy, inflamed skin. The trial enrolls healthy adult men and adults with atopic dermatitis to see how safe and tolerable the ointment is wh…
Phase 1 • Sponsor: HK inno.N Corporation • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a new acid blocker match the standard for protecting NSAID Users' stomachs?
Prevention CompletedResearchers are testing whether tegoprazan 25 mg works as well as lansoprazole 15 mg at preventing stomach and duodenal ulcers in people who take NSAID pain relievers for at least six months. The trial enrolls adults aged 60 or older, or younger adults with a history of such ulce…
Phase 3 • Sponsor: HK inno.N Corporation • Aim: Prevention
Last updated Sep 16, 2026 00:00 UTC